FDA eyes regulating sterile-product compounding
Where To Look for Help to use new drugs because they fear inadequate reimbursement, some critics have said. The only way Medicare will pay for drugs not on the pass-through list is as a part of the associated APC group.
Pharmacy and billing. How pharmacists are affected by outpatient PPS depends largely upon the billing mechanisms in place at a hospital, said Patricia C. Kienle, System Director of Pharmacy Services, Owen Healthcare, at Mercy Health Partners in Wilkes-Barre, Pennsylvania. When a medication order is filled, the line item is transmitted electronically to the billing department. Each drug is assigned several codes used in submitting Medicare claims. Pharmacists often refer to HCPCS codes as "J codes" because, until recently, codes assigned to drugs always began with the letter J. (Some drug codes now begin with C, Q, or S.) Revenue codes assigned to drugs are not drug-specific; they denote broad categories under which drugs are grouped on the basis of various factors, including a drug's pass-through status.
It is vital that a hospital have on file in its computer system the correct codes for each drug used, Kienle said, so that billing will be correct each time a drug is dispensed. Some hospitals already have the HCPCS codes on their systems, but others have not used the codes in the past because their use in Medicare claims was not mandatory. Now, the pressure is on to update systems, because reimbursement hinges on proper coding. All drugs, even those that are grouped within an APC, should be billed with the correct codes, because HCFA will use these data to update APC payments in the future.
Kienle is concerned about the potential for both billing errors and medication errors with the HCPCS coding system. There is considerable variation in the assignment of codes; some products that are available in several package sizes have only one code, while others have a different code for each package size. Often, said Kienle, "the package size available commercially does not match the HCPCS code."
For example, the HCPCS code as-signed to paclitaxel injection corresponds to the 30-mg vial, but Kienle's institutions also stock the 100-mg package of the drug. To ensure billing accuracy for Medicare purposes, the 30-mg vial is the only package size for paclitaxel that appears on the pharmacy computer system. Pharmacists must enter the dose on the basis of the number of 30-mg vials used, even if they actually used a larger vial or a partial vial. "We have to manip-I roning out the details of pharmacy compounding regulations, FDA has zeroed in on the compounding of sterile drug products. An FDA "concept paper" published June 29 proposes to classify as illegal any sterile drug product not compounded in accordance with chapter 1206 of The United States Pharmacopeia (USP). The chapter, titled "Sterile Drug Products for Home Use," does not by itself carry any legal weight. Furthermore, it is currently under revision.
FDA's entry into pharmacy regulation. Enactment of the Food and Drug Administration Modernization Act of 1997 (FDAMA) gave the agency the responsibility of setting limits, in the interest of public safety, on legal compounding by pharmacies and physicians. Part of this responsibility, according to FDAMA, involves identifying which drug products "present demonstrable difficulties for compounding that reasonably demonstrate an adverse effect on the safety or effectiveness of those drug products."
FDA's new tack-compiling a list of To keep abreast of developments in outpatient PPS, pharmacists can check out the following HCFA resources:
• An electronic mail service that provides information on changes (subscribe at www.hcfa.gov/medlearn/ listserv.htm) • The list of transitional pass-through drugs as of March 12, 2000, available in PDF format or as a Microsoft Excel spreadsheet (www.hcfa.gov/medicare/passthru.htm) • A July 26 memo providing more details on some of the drugs on the pass-through list, available in both PDF (www.hcfa.gov/medicare/0726opps.pdf) and Microsoft Word format (www.hcfa.gov/medicare/ 0726opps.doc); see section I (For a cumulative list of information on pass-through drugs, cut the longer descriptors from the Word version and paste them into the spreadsheet version of the original passthrough list.) • Section IV (mislabeled in the document as section III) of the July 26 memo, providing a list of drugs not eligible for pass-through payment but classified in separate APCs. Health-system pharmacist Kienle suggests these additional resources:
• The hospital's director of billing, who will likely have a copy of a manual with extensive information on Juhl and McBurney asked whether a physician who adds lidocaine to a vial of, say, a corticosteroid before administering the injection would be compounding difficult-to-compound drug productscenters on identifying drug delivery systems that, when compounded rather than manufactured, pose a danger to patients. In its concept paper, FDA named four drug delivery systems that pharmacists, physicians, and the people they supervise may not compound: sterile drug products not compounded in accordance with USP chapter 1206, metered-dose inhalers, dry-powder inhalers, and transdermal systems.
Members of FDA's Pharmacy Compounding Advisory Committee seemed to agree that the proposal in general makes sense-and that the agency should also look at other drug delivery systems, such as enteric-coated products. The committee met July 13-14 to discuss and hear comments on the concept paper and to answer questions formally posed by FDA.
Shelly Capps, speaking to the committee on behalf of the International Academy of Compounding Pharmacists, said her organization objects to the tack proposed by FDA because FDAMA specifically refers to drug products that are difficult to compound, not techniques that are difficult to perform.
Before the passage of FDAMA, the federal government left the regulation of pharmacy practice to state boards of pharmacy. But FDA's Jane Axelrad, associate director for policy at the Center for Drug Evaluation and Research, intimated to the advisory committee that some boards, particularly one in a southern state, may not act as aggressively as they should to protect the public against unsafe compounding practices. National Association of Boards of Pharmacy (NABP) Executive Director Carmen A. Catizone is a member of the compounding advisory committee but was not present at the meeting.
ASHP Executive Vice President Henri R. Manasse, Jr., told the committee the Society believes FDA has a role in, but should not take control of, ensuring that compounding pharmacists and others follow the standards in USP chapter 1206 and the ASHP Guidelines on Quality Assurance for Pharmacy-Prepared Sterile Products.
"We strongly recommend that the FDA delegate to state boards of pharmacy the responsibility for overseeing pharmacists' adherence to those standards, rather than assume this responsibility directly," Manasse said in his prepared statement.
Noting that none of ASHP's guidelines have the force of law behind them, Manasse said, "Perhaps the translation of ASHP's guidelines into state laws, particularly that govern the compounding of sterile products, is a reasonable direction." He said the Society is currently comparing its guidelines against NABP's model law on compounding.
A clear preference for USP chapter 1206. Discussion of FDA's proposal by the advisory committee revealed a clear preference for the USP chapter over ASHP's recently revised sterile compounding guidelines. According to the FDA concept paper, the USP chapter "describes more comprehensive controls" than the ASHP guidelines.
Compounding advisory committee chair Randy P. Juhl, dean of University of Pittsburgh's pharmacy school, said he favors the USP chapter because it must regularly undergo revision, unlike the ASHP a low-risk sterile product from sterile components and would therefore have to comply with USP chapter 1206. Axelrad said that the committee should disregard this line of questioning and that she would ask that revisions to the USP chapter take this practice issue into consideration. Manasse said ASHP objects to exclusion of its guidelines as a basis for ensuring the potency, purity, and quality of sterile drug products compounded in pharmacies. "There is little practical difference in content between the ASHP and USP documents," he said.
Loyd V. Allen, Jr., who chairs the committee revising USP chapter 1206, serves as editor-in-chief of the International Journal of Pharmaceutical Compounding, and sits on the FDA committee, asked Manasse to provide a summary of how the ASHP guidelines differ from or add to the draft chapter. Allen says his USP committee intends to harmonize the various guidelines and other documents on sterile drug compounding.
The next step. FDA gave the public until August 15 to submit written comments on the concept paper. The agency will consider these comments in formulating its proposed rule on pharmacy compounding. When the proposed rule is published, the public will again have the opportunity to comment.
-Cheryl A. Thompson
Continued from page 1564
Continued on page 1573
Oral mesalamine prodrug approved for active ulcerative colitis S alix Pharmaceuticals has received approval to market balsalazide disodium (Colazal) oral capsules for treatment of mildly to moderately active ulcerative colitis. Salix expects to introduce Colazal in the first quarter of 2001.
Balsalazide, a prodrug, is delivered to the colon intact. There it is cleaved enzymatically to produce mesalamine (5aminosalicylic acid).
The recommended dosage of balsalazide disodium is 2.25 g three times daily for eight weeks. This dosage delivers 2.4 g of mesalamine each day to the colon. In clinical trials, this dosage was associated with symptomatic improvement in patients with active mild or moderate ulcerative colitis. Treatment was continued for up to 12 weeks.
Balsalazide is not labeled for use as maintenance therapy.
The most common adverse events reported by patients taking balsalazide are headache, abdominal pain, nausea, and diarrhea.
Colazal will be available as 750-mg capsules in bottles of 280.
-JLM
HMOs exiting Medicare will affect nearly 1 million C hanges in Medicare managed care contracts at the end of this year will force 934,000 beneficiaries to look elsewhere for care. Sixty-five Medicare+ Choice HMOs are not renewing current contracts and 53 are reducing their service areas.
Medicare+Choice HMOs tend to provide benefits, such as outpatient prescription drug coverage, that are not available in fee-for-service Medicare, and managed care costs generally have increased faster than costs in fee-for-service Medicare. When Medicare+Choice plans decide they cannot charge premiums or reduce benefits to compete, they withdraw from the program.
"Clearly, the volatility of the Medicare managed care market underscores the need for Congress to enact the President's legislative proposal to modernize and strengthen Medicare," said Health Care Financing Administration (HCFA) head Nancy-Ann DeParle in a July 24 announcement of the nonrenewals. HCFA cited General Accounting Office testimo-ny that, in past years, plans that withdraw tend to be those that have entered a market recently, have few enrollees, or were unable to establish or maintain provider networks.
HCFA noted that about 85% of current Medicare+Choice beneficiaries will be able to continue in 2001 with their current Medicare HMO. But the number of beneficiaries affected by plan pullouts was higher than in the past two years and exceeded predictions by the managed care industry. For 17% of the beneficiaries, about 159,000 people, no Medi-care+Choice options will be available. All will be able to return to fee-for-service Medicare.
Of a total of 39 million enrollees in Medicare, 6.2 million are in HMOs. More than one fourth of those managed care enrollees will have been affected by plan withdrawals in 2001, 2000, and 1999 combined.
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